Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen

Noton K. Dutta, Rongjun He, Michael L. Pinn, Yantao He, Francis Burrows, Zhong-Yin Zhang, Petros C. Karakousis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Novel drugs are required to shorten the duration of treatment for tuberculosis (TB) and to combat the emergence of drug resistance. One approach has been to identify and target Mycobacterium tuberculosis (Mtb) virulence factors, which promote the establishment of TB infection and pathogenesis. Mtb produces a number of virulence factors, including two protein tyrosine phosphatases (PTPs), mPTPA and mPTPB, to evade the antimicrobial functions of host macrophages. To assess the therapeutic potential of targeting the virulent Mtb PTPs, we developed highly potent and selective inhibitors of mPTPA (L335-M34) and mPTPB (L01-Z08) with drug-like properties. We tested the bactericidal activity of L335-M34 and L01-Z08 alone or together in combination with the standard anti-tubercular regimen of isoniazid-rifampicin-pyrazinamide (HRZ) in the guinea pig model of chronic TB infection, which faithfully recapitulates some of the key histological features of human TB lesions. Following a single dose of L335-M34 50 mg/kg and L01-Z08 20 mg/kg, plasma levels were maintained at levels 10-fold greater than the biochemical IC50 for 12-24 h. Although neither PTP inhibitor alone significantly enhanced the antibacterial activity of HRZ, dual inhibition of mPTPA and mPTPB in combination with HRZ showed modest synergy, even after 2 weeks of treatment. After 6 weeks of treatment, the degree of lung inflammation correlated with the bactericidal activity of each drug regimen. This study highlights the potential utility of targeting Mtb virulence factors, and specifically the Mtb PTPs, as a strategy for enhancing the activity of standard anti-TB treatment.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalACS Infectious Diseases
Volume2
Issue number3
DOIs
StatePublished - Mar 11 2016

Fingerprint

Protein Tyrosine Phosphatases
Mycobacterium tuberculosis
Tuberculosis
Virulence Factors
Pharmaceutical Preparations
Pyrazinamide
Isoniazid
Rifampin
Infection
Drug Resistance
Inhibitory Concentration 50
Pneumonia
Guinea Pigs
Macrophages

Keywords

  • activity
  • bactericidal
  • chemotherapy
  • guinea pig
  • inhibitors
  • isoniazid
  • Mycobacterium tuberculosis
  • pharmacokinetics
  • protein tyrosine phosphatases
  • pyrazinamide
  • rifampin
  • sterilizing
  • virulence factors

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen. / Dutta, Noton K.; He, Rongjun; Pinn, Michael L.; He, Yantao; Burrows, Francis; Zhang, Zhong-Yin; Karakousis, Petros C.

In: ACS Infectious Diseases, Vol. 2, No. 3, 11.03.2016, p. 231-239.

Research output: Contribution to journalArticle

Dutta, Noton K. ; He, Rongjun ; Pinn, Michael L. ; He, Yantao ; Burrows, Francis ; Zhang, Zhong-Yin ; Karakousis, Petros C. / Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen. In: ACS Infectious Diseases. 2016 ; Vol. 2, No. 3. pp. 231-239.
@article{e529f74f4ae543dd9e3c2ce694807985,
title = "Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen",
abstract = "Novel drugs are required to shorten the duration of treatment for tuberculosis (TB) and to combat the emergence of drug resistance. One approach has been to identify and target Mycobacterium tuberculosis (Mtb) virulence factors, which promote the establishment of TB infection and pathogenesis. Mtb produces a number of virulence factors, including two protein tyrosine phosphatases (PTPs), mPTPA and mPTPB, to evade the antimicrobial functions of host macrophages. To assess the therapeutic potential of targeting the virulent Mtb PTPs, we developed highly potent and selective inhibitors of mPTPA (L335-M34) and mPTPB (L01-Z08) with drug-like properties. We tested the bactericidal activity of L335-M34 and L01-Z08 alone or together in combination with the standard anti-tubercular regimen of isoniazid-rifampicin-pyrazinamide (HRZ) in the guinea pig model of chronic TB infection, which faithfully recapitulates some of the key histological features of human TB lesions. Following a single dose of L335-M34 50 mg/kg and L01-Z08 20 mg/kg, plasma levels were maintained at levels 10-fold greater than the biochemical IC50 for 12-24 h. Although neither PTP inhibitor alone significantly enhanced the antibacterial activity of HRZ, dual inhibition of mPTPA and mPTPB in combination with HRZ showed modest synergy, even after 2 weeks of treatment. After 6 weeks of treatment, the degree of lung inflammation correlated with the bactericidal activity of each drug regimen. This study highlights the potential utility of targeting Mtb virulence factors, and specifically the Mtb PTPs, as a strategy for enhancing the activity of standard anti-TB treatment.",
keywords = "activity, bactericidal, chemotherapy, guinea pig, inhibitors, isoniazid, Mycobacterium tuberculosis, pharmacokinetics, protein tyrosine phosphatases, pyrazinamide, rifampin, sterilizing, virulence factors",
author = "Dutta, {Noton K.} and Rongjun He and Pinn, {Michael L.} and Yantao He and Francis Burrows and Zhong-Yin Zhang and Karakousis, {Petros C.}",
year = "2016",
month = "3",
day = "11",
doi = "10.1021/acsinfecdis.5b00133",
language = "English (US)",
volume = "2",
pages = "231--239",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen

AU - Dutta, Noton K.

AU - He, Rongjun

AU - Pinn, Michael L.

AU - He, Yantao

AU - Burrows, Francis

AU - Zhang, Zhong-Yin

AU - Karakousis, Petros C.

PY - 2016/3/11

Y1 - 2016/3/11

N2 - Novel drugs are required to shorten the duration of treatment for tuberculosis (TB) and to combat the emergence of drug resistance. One approach has been to identify and target Mycobacterium tuberculosis (Mtb) virulence factors, which promote the establishment of TB infection and pathogenesis. Mtb produces a number of virulence factors, including two protein tyrosine phosphatases (PTPs), mPTPA and mPTPB, to evade the antimicrobial functions of host macrophages. To assess the therapeutic potential of targeting the virulent Mtb PTPs, we developed highly potent and selective inhibitors of mPTPA (L335-M34) and mPTPB (L01-Z08) with drug-like properties. We tested the bactericidal activity of L335-M34 and L01-Z08 alone or together in combination with the standard anti-tubercular regimen of isoniazid-rifampicin-pyrazinamide (HRZ) in the guinea pig model of chronic TB infection, which faithfully recapitulates some of the key histological features of human TB lesions. Following a single dose of L335-M34 50 mg/kg and L01-Z08 20 mg/kg, plasma levels were maintained at levels 10-fold greater than the biochemical IC50 for 12-24 h. Although neither PTP inhibitor alone significantly enhanced the antibacterial activity of HRZ, dual inhibition of mPTPA and mPTPB in combination with HRZ showed modest synergy, even after 2 weeks of treatment. After 6 weeks of treatment, the degree of lung inflammation correlated with the bactericidal activity of each drug regimen. This study highlights the potential utility of targeting Mtb virulence factors, and specifically the Mtb PTPs, as a strategy for enhancing the activity of standard anti-TB treatment.

AB - Novel drugs are required to shorten the duration of treatment for tuberculosis (TB) and to combat the emergence of drug resistance. One approach has been to identify and target Mycobacterium tuberculosis (Mtb) virulence factors, which promote the establishment of TB infection and pathogenesis. Mtb produces a number of virulence factors, including two protein tyrosine phosphatases (PTPs), mPTPA and mPTPB, to evade the antimicrobial functions of host macrophages. To assess the therapeutic potential of targeting the virulent Mtb PTPs, we developed highly potent and selective inhibitors of mPTPA (L335-M34) and mPTPB (L01-Z08) with drug-like properties. We tested the bactericidal activity of L335-M34 and L01-Z08 alone or together in combination with the standard anti-tubercular regimen of isoniazid-rifampicin-pyrazinamide (HRZ) in the guinea pig model of chronic TB infection, which faithfully recapitulates some of the key histological features of human TB lesions. Following a single dose of L335-M34 50 mg/kg and L01-Z08 20 mg/kg, plasma levels were maintained at levels 10-fold greater than the biochemical IC50 for 12-24 h. Although neither PTP inhibitor alone significantly enhanced the antibacterial activity of HRZ, dual inhibition of mPTPA and mPTPB in combination with HRZ showed modest synergy, even after 2 weeks of treatment. After 6 weeks of treatment, the degree of lung inflammation correlated with the bactericidal activity of each drug regimen. This study highlights the potential utility of targeting Mtb virulence factors, and specifically the Mtb PTPs, as a strategy for enhancing the activity of standard anti-TB treatment.

KW - activity

KW - bactericidal

KW - chemotherapy

KW - guinea pig

KW - inhibitors

KW - isoniazid

KW - Mycobacterium tuberculosis

KW - pharmacokinetics

KW - protein tyrosine phosphatases

KW - pyrazinamide

KW - rifampin

KW - sterilizing

KW - virulence factors

UR - http://www.scopus.com/inward/record.url?scp=84969228128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969228128&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.5b00133

DO - 10.1021/acsinfecdis.5b00133

M3 - Article

VL - 2

SP - 231

EP - 239

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 3

ER -